Warner Chilcott: Doryx Kept Changing, and the Defendants Won

Warner Chilcott product hopping cases put the pharmacy counter at the center of a drug launch: change the product being prescribed, and the generic may lose its route to the patient. In the Doryx dispute, Mylan alleged that Warner Chilcott and Mayne Pharma repeatedly changed the drug to block generic competition. Capsules became tablets, strengths changed and tablets gained score lines. Each change required new approval for generics seeking to match the latest Doryx. For an insider working on a formulation, launch or withdrawal, the revealing part is how those product decisions changed what could happen at the pharmacy counter.

The Third Circuit’s September 28, 2016 opinion explains why the defendants won. Mylan had failed to show monopoly power in the market for oral tetracyclines used to treat acne. It also failed to show that the Doryx changes excluded competition. Other plaintiffs settled their Doryx cases, but Mylan pursued its claims and lost.

Mayne Pharma manufactured Doryx, and Warner Chilcott distributed it in the United States. Their licensing agreement made Warner the exclusive U.S. distributor and Mayne its exclusive manufacturer and supplier. Mayne also agreed to withdraw its own generic Doryx while the companies developed a tablet to replace the capsule.

Warner Chilcott’s Separate False Claims Act Case

Warner Chilcott agreed to pay $102.06 million to resolve civil allegations in a separate pharmaceutical fraud case. The Justice Department’s civil allegations concerned physician payments, falsified prior authorizations and unsupported claims of Actonel’s superiority. For someone working in drug sales or reimbursement, the connection is concrete: what drove the prescription, and what the payer was told to get it covered.

For insiders whose information concerns false government claims, a whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our whistleblower experts work with you to turn evidence of false payer submissions or prescribing payments into your strongest pharmaceutical whistleblower case.

How the Doryx Product Switch Worked

Doryx is delayed-release doxycycline hyclate, an oral antibiotic used to treat severe acne. Mylan’s product-hopping allegation concerned the changing form of that drug and the effect on generic substitution. Mylan argued that the changes offered little or no therapeutic benefit while repeatedly frustrating its efforts to sell a substitutable generic.

The commercial advantage of a generic runs through the prescription. As the court explained the approval system, an abbreviated new drug application lets a generic manufacturer rely on the brand’s earlier approval. The generic must demonstrate pharmaceutical equivalence and bioequivalence to that product. A successful showing can earn an AB rating, which connects the approval to state laws permitting or requiring pharmacists to dispense a lower-cost equivalent unless the prescriber directs otherwise.

That makes the product being prescribed crucial. Approval to substitute for an old capsule does not supply approval to substitute for a new tablet. The opinion describes how each Doryx change required generic manufacturers to file and await a new application if they wanted an AB rating for the newest version.

The prescribing and purchasing decisions also sit with different people. The doctor selects the medicine, while an insurer often pays much of the bill. Automatic substitution gives a lower-cost generic a way into that transaction without first persuading the doctor to write a different prescription. When a switch blocks that substitution, patients and insurers lose that way to obtain the cheaper drug.

Four Changes to the Product Generics Had to Match

The Doryx case concerned four principal changes, followed by withdrawals of older versions. The opinion’s product history follows the changes through both the brand’s launch plans and Mylan’s efforts to catch up.

1. Capsules became tablets in 2005. Warner and Mayne introduced tablets. They stopped selling capsules to wholesalers, removed the capsules from Warner’s website and worked with retailers to make prescriptions for Doryx point to the tablet. They told wholesalers, retailers and doctors that the tablets had replaced the capsules, destroyed some remaining capsule stock and bought back some inventory.
2. A higher-strength tablet arrived in 2008. The new tablet had a score line that allowed it to be divided into two doses. The companies shifted their marketing toward it from the smaller, unscored tablets.
3. The smaller tablets gained scores in 2009. The Food and Drug Administration approved scored versions of the smaller tablets. Mylan had already applied for approval of its generic tablets, but the new scoring required changes to its design to obtain an AB rating, contributing to the delay in approval.
4. The larger tablet gained a second score in 2011. After applying for approval of the dual-scored tablet, the companies pulled the smaller single-scored tablets. Once the Food and Drug Administration approved the new version, they stopped distributing the single-scored larger tablet too.

Mylan called the capsule withdrawal a hard switch. Its allegation reached beyond introducing a new product: the companies also removed stock and redirected the prescribing and dispensing business toward the replacement.

The sequence left Mylan chasing a moving target. By the time its smaller scored tablets gained approval, Warner and Mayne were focused on the larger tablet. When Mylan’s single-scored larger tablet gained approval, the brand was already marketing the dual-scored version.

Why Warner Chilcott Won the Doryx Market Power Argument

The Doryx summary judgment turned on which drugs actually competed with Warner Chilcott’s product. Mylan wanted the market limited to branded and generic Doryx. The court instead included all oral tetracyclines prescribed to treat acne. In that market, the defendants’ share never exceeded 18%.

That conclusion came from the way the business worked. Dermatologists regarded the drugs as similarly effective for acne. Insurers encouraged substitution with less expensive tetracyclines, sometimes removing Doryx from coverage or restricting reimbursement.

The pricing evidence reinforced that picture. When Doryx became more expensive, its sales fell and sales of other tetracyclines rose.

The district court accepted, for argument’s sake, that the switches were meant mainly to delay generic entry. Even on that account, Warner and Mayne won. Mylan still had to show what the switches did to competition in the wider market.

Mylan Still Reached the Market

The court also rejected Mylan’s claim that the switches excluded it from competition. Mylan successfully introduced generic Doryx tablets and obtained 180 days of exclusive selling rights for its smaller tablets. The opinion reported $146.9 million in generic-tablet profits. For part of the period, Mylan even priced its tablets above branded Doryx.

The court found that doctors could still prescribe generic Doryx, pharmacists could substitute when medically appropriate and patients could ask for it. It also found that Mylan had relied on automatic substitution instead of attempting to market the generic directly. Automatic substitution mattered to the business, but the court considered the other ways Mylan could reach a buyer too.

Warner and Mayne also had product-specific explanations the court credited. Doxycycline capsules had been linked to esophageal problems. Score lines allowed patients to divide a tablet for more individualized dosing.

Why Namenda Produced a Different Result

The Namenda product-switch case produced a temporary court order keeping the older drug available. In its comparison with Namenda, the Third Circuit described an effort to move patients from Namenda IR to Namenda XR as patent protection approached its end.

Doryx presented different conditions. Its capsules had been available for more than twenty years, with generic manufacturers free to develop their own versions. No approaching patent expiration drove the switches, and competitors were already selling other oral tetracyclines. The court’s comparison put patent timing and the competing drugs alongside the withdrawal itself.

The Third Circuit also identified circumstances that could produce a different outcome: insignificant design or formula changes combined with coercion, pressure on physician prescribing or blatant misrepresentations about a generic. For someone inside the business, that directs attention to the communications accompanying the launch. What doctors, pharmacies and wholesalers were told can matter alongside the formulation and the decision to withdraw the predecessor.

You Saw the Decisions Behind the Launch

If you worked on a drug switch and know what prescribers or payers were told, speak to one of our whistleblower experts about the launch plans, withdrawal instructions or reimbursement messages behind it. We help turn evidence of false government claims into a pharmaceutical whistleblower case, bring in pharmaceutical whistleblower lawyers who understand drug promotion and reimbursement, and stay beside you as the case develops.